DPYSL2 and urinary bladder cancer: Moreover, DPYSL2 deficiency inhibited the malignant behavior and epithelial–mesenchymal transition in bladder cancer cells [43], thus the downregulation of DPYSL2 observed in the UBT after RTX administration may suggest the anti-cancer properties of the toxin.